Evidence map›Paper›PMID 27510901›Full record

ArticleScience translational medicine2016

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy.

Akanksha Chhabra, Aaron M Ring, Kipp Weiskopf, Peter John Schnorr, Sydney Gordon, Alan C Le, Hye-Sook Kwon, Nan Guo Ring, Jens Volkmer, Po Yi Ho and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 166 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  9. Article
  10. Article
  11. Clinical hematopoietic stem cell-based gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Deciphering the role of CD47 in cancer immunotherapy.Journal of advanced research · 2024
    Review
  18. Article
  19. Article
  20. Gene therapy for sickle cell disease.Hematology. American Society of Hematology. Education Program · 2023
    Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Akanksha ChhabraBlood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
Aaron M RingInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Kipp WeiskopfInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Peter John SchnorrBlood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
Sydney GordonInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Alan C LeBlood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
Hye-Sook KwonBlood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA.
Nan Guo RingInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jens VolkmerInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Po Yi HoInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Serena TsengInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Irving L WeissmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA.
Judith A ShizuruBlood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. jshizuru@stanford.edu.
Stanford University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8M
HSC Diversity: Regulation by Clonal Selection vs Epigenetic InductionR01CA086065 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2000 to 2017
$6.9M
HOMING RECEPTOR DETERMINANTS ON HSCR01HL058770 · NHLBI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 1998 to 2013
$3.9M
Molecular Mechanisms of Cellular MechanicsR01GM073655 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI SCHULTEN, KLAUS · 2006 to 2009
$1.0M
National Institute of General Medical Sciences R01 GM073655NCI NIH HHS R01 CA086065NHLBI NIH HHS R01 HL058770NIGMS NIH HHS T32 GM007365
6 · The paper itself

Abstract

Hematopoietic stem cell (HSC) transplantation can cure diverse diseases of the blood system, including hematologic malignancies, anemias, and autoimmune disorders. However, patients must undergo toxic conditioning regimens that use chemotherapy and/or radiation to eliminate host HSCs and enable donor HSC engraftment. Previous studies have shown that anti-c-Kit monoclonal antibodies deplete HSCs from bone marrow niches, allowing donor HSC engraftment in immunodeficient mice. We show that host HSC clearance is dependent on Fc-mediated antibody effector functions, and enhancing effector activity through blockade of CD47, a myeloid-specific immune checkpoint, extends anti-c-Kit conditioning to fully immunocompetent mice. The combined treatment leads to elimination of >99% of host HSCs and robust multilineage blood reconstitution after HSC transplantation. This targeted conditioning regimen that uses only biologic agents has the potential to transform the practice of HSC transplantation and enable its use in a wider spectrum of patients.

Indexed as

AnimalsCD47 AntigenDNA-Binding ProteinsErythrocytesFlow CytometryHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansImmunotherapyMiceMice, Mutant StrainsReceptors, FcCD47 AntigenDNA-Binding ProteinsRag2 protein, mouseReceptors, Fc

Identifiers

PMID27510901
PMCPMC6668627
OpenAlexW2500588363

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.